Entera Bio annual r&d spending
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Entera Bio R&D Spending Growth & History (ENTX)
Entera Bio's r&d spending was $6.0M for fiscal 2025.
View full Entera Bio company overviewEntera Bio annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.0M | $1.5M | +33.45% |
| 2024 | 2024-12-31 | $4.5M | −$11,000 | −0.24% |
| 2023 | 2023-12-31 | $4.5M | −$1.3M | −22.88% |
| 2022 | 2022-12-31 | $5.8M | −$923,000 | −13.63% |
| 2021 | 2021-12-31 | $6.8M | $389,000 | +6.10% |
| 2020 | 2020-12-31 | $6.4M | −$817,000 | −11.35% |
| 2019 | 2019-12-31 | $7.2M | −$1.3M | −15.48% |
| 2018 | 2018-12-31 | $8.5M | $5.8M | +207.73% |
| 2017 | 2017-12-31 | $2.8M | $120,000 | +4.53% |
| 2016 | 2016-12-31 | $2.6M | — | — |
Entera Bio quarterly r&d spending
Q2.19
Q2.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.2M | $1.7M | +110.59% |
| Q1 2026 | 2026-03-31 | $2.3M | $1.1M | +100.45% |
| Q4 2025 | 2025-12-31 | $1.7M | $517,000 | +43.05% |
| Q3 2025 | 2025-09-30 | $1.6M | $166,000 | +11.24% |
| Q2 2025 | 2025-06-30 | $1.5M | $434,000 | +39.96% |
| Q1 2025 | 2025-03-31 | $1.1M | $388,000 | +52.79% |
| Q4 2024 | 2024-12-31 | $1.2M | $201,000 | +20.10% |
| Q3 2024 | 2024-09-30 | $1.5M | $107,000 | +7.81% |
| Q2 2024 | 2024-06-30 | $1.1M | −$123,000 | −10.17% |
| Q1 2024 | 2024-03-31 | $735,000 | −$196,000 | −21.05% |
| Q4 2023 | 2023-12-31 | $1.0M | −$351,000 | −25.98% |
| Q3 2023 | 2023-09-30 | $1.4M | −$43,000 | −3.04% |
| Q2 2023 | 2023-06-30 | $1.2M | −$185,000 | −13.27% |
| Q1 2023 | 2023-03-31 | $931,000 | −$759,000 | −44.91% |
| Q4 2022 | 2022-12-31 | $1.4M | −$1.3M | −49.00% |
| Q3 2022 | 2022-09-30 | $1.4M | −$358,000 | −20.21% |
| Q2 2022 | 2022-06-30 | $1.4M | $167,000 | +13.61% |
| Q1 2022 | 2022-03-31 | $1.7M | $566,000 | +50.36% |
| Q4 2021 | 2021-12-31 | $2.6M | — | — |
| Q3 2021 | 2021-09-30 | $1.8M | — | — |
| Q2 2021 | 2021-06-30 | $1.2M | −$784,000 | −38.99% |
| Q1 2021 | 2021-03-31 | $1.1M | — | — |
| Q2 2020 | 2020-06-30 | $2.0M | $598,000 | +42.32% |
| Q2 2019 | 2019-06-30 | $1.4M | — | — |
Entera Bio r&d spending trends
Over the last five fiscal years, Entera Bio's r&d spending decreased from $6.4M to $6.0M, a change of −$378,000. The latest reported quarter, Q2 2026, shows $3.2M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Entera Bio source filings ↗